MENU
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2026 All rights reserved. Tickeron Inc.
OTLK
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Outlook Therapeutics (OTLK) Ownership - Who owns Outlook Therapeutics?

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications... Show more

Industry: #Biotechnology
#MovingAverage#Momentum#MACD#Pattern#RSI#Stochastic#Aroon#Bollinger

Profile

Industry
Biotechnology
Address
111 S. Wood Avenue
Phone
+1 609 619-3990
Employees
17
Web
https://www.outlooktherapeutics.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
234.77M
P/E Ratio
0.59
Total Cash
7.75M
Projected Growth
N/A
Total Debt
27.19M
Revenue
333.14K
Risk (Beta)
1.69
Dividend Yield
N/A
Total Cash/Share
0.05
Total Debt/Equity
N/A
Revenue/Share
0.01 USD as % of share price
View a ticker or compare two or three
GO
VS
Compare
VS
Compare
OTLK
Setup
Setup
Daily Signal:
Description
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
View AI-Driven Trading for OTLK
A.I. Advisor
published General Information

General Information

a manufacturer of biosimilar versions of biopharmaceuticals

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
111 S. Wood Avenue
Phone
+1 609 619-3990
Employees
17
Web
https://www.outlooktherapeutics.com